Clinical trial · Observational
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
NCT02072967CI-TRIAL-00021013completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ribomustin | Other | — | UNRESOLVED |
| rituximab | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ribomustin and rituximab
- interventionNames
- Other: Ribomustin
- Other: rituximab
Primary outcomes (1)
- measure
- Overall response rate
- timeFrame
- 90 days post-treatment
Secondary outcomes (1)
- measure
- Adverse drug reactions
- timeFrame
- up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Doctor's decision to prescribe Ribomustin and rituximab combined therapy for the treatment of relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma (iNHL) * Informed Consent Form for personal data handling signed by the program participant, authorized by the Independent Ethics Committee * Eastern Cooperative Oncology Group (ECOG) status \< 2. * Confirmed relapse or disease progression of B-cell CD20+ Non-Hodgkin's Lymphoma (lymphocytic, lymphocytoplasmocytic, follicular, marginal zone) after minimum one line of iNHL treatment * Patients with relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma with current or planned Ribomustin and rituximab combined therapy with following rituximab maintenance therapy Exclusion Criteria: * Indolent Non-Hodgkin's Lymphoma transformation * Lymphoma with central nervous system (CNS) involvement * Presence of second malignant tumor. * Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment. * Contraindications for Ribomustin usage in accordance with product label * Contradictions for rituximab usage in accordance with product label
References
Publications (0)
Data not yet available
No reference posted for this study.